Tower Research Capital LLC TRC Decreases Stake in Invesco Bloomberg Analyst Rating Improvers ETF (NYSEARCA:UPGD)

Tower Research Capital LLC TRC cut its holdings in shares of Invesco Bloomberg Analyst Rating Improvers ETF (NYSEARCA:UPGD) by 3.7% during the fourth quarter, HoldingsChannel.com reports. The fund owned 17,842 shares of the company’s stock after selling 692 shares during the period. Tower Research Capital LLC TRC’s holdings in Invesco Bloomberg Analyst Rating Improvers ETF were worth $1,233,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Raymond James Financial Inc. acquired a new position in shares of Invesco Bloomberg Analyst Rating Improvers ETF during the 4th quarter valued at about $13,460,000. Morey & Quinn Wealth Partners LLC acquired a new position in Invesco Bloomberg Analyst Rating Improvers ETF in the 4th quarter valued at about $351,000. Millstone Evans Group LLC acquired a new position in Invesco Bloomberg Analyst Rating Improvers ETF in the 4th quarter valued at about $312,000. Smith Moore & CO. grew its stake in shares of Invesco Bloomberg Analyst Rating Improvers ETF by 14.3% in the 4th quarter. Smith Moore & CO. now owns 3,195 shares of the company’s stock valued at $221,000 after buying an additional 400 shares during the period. Finally, Wells Fargo & Company MN acquired a new stake in shares of Invesco Bloomberg Analyst Rating Improvers ETF during the 4th quarter worth approximately $30,000.

Invesco Bloomberg Analyst Rating Improvers ETF Stock Performance

UPGD opened at $67.18 on Friday. The stock has a market capitalization of $102.11 million, a PE ratio of 21.00 and a beta of 1.06. Invesco Bloomberg Analyst Rating Improvers ETF has a one year low of $61.76 and a one year high of $75.85. The business’s 50 day moving average price is $68.71 and its 200 day moving average price is $70.83.

Invesco Bloomberg Analyst Rating Improvers ETF Profile

The Invesco Bloomberg Analyst Rating Improvers ETF (UPGD) is an exchange-traded fund that is based on the Bloomberg ANR Improvers index. The fund tracks an equal-weighted index of large-and mid-cap US stocks that are identified to have the most improved consensus ratings based on analyst recommendations.